Management

Dr Michael L. Selley, FRACI

Chairman and Chief Executive Officer

Dr Selley has considerable experience in pharmaceutical research and development. He was the founder and Chief Scientific Officer of Nuon Therapeutics, Inc., the founder of Xenexus Pharmaceuticals Pty. Ltd and a cofounder of Cherwell Therapeutics Ltd. Dr Selley served as Chief of Staff to the Minister for Science and Technology in the Parliament of Australia and held academic appointments at the John Curtin School of Medical Research in the Institute of Advanced Studies at the Australian National University. He has worked in the international pharmaceutical industry in a number of roles, including drug discovery, pharmacology, toxicology, and clinical trials.

Scientific Advisers

Prof. Scott L. Friedman, M.D.

Prof. Scott L. Friedman, M.D., is Fishberg Professor of Medicine, Professor of Pharmacology and Systems Therapeutics, Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai Hospital, New York. Prof. Friedman is responsible for the discovery of a novel tumour suppressor gene, KLF6 that is inactivated in a number of human cancers, including primary liver cancer. He has performed pioneering research into the underlying causes of scarring, or fibrosis, associated with chronic liver disease, which affects millions worldwide. He was among the first to isolate and characterise the hepatic stellate cell, which is the key cell type responsible for scar production in liver. He has been a Member of the Scientific Advisory Board at Pro-Pharmaceuticals Inc., since June 2008 and Scholar Rock, Inc., since January 4, 2016. He serves as a Member of the Scientific Advisory Board at Intercept Pharmaceuticals, Inc., Tobira Therapeutics, Inc, Exalenz Bioscience Ltd. and BiOrion Technologies BV. He has been a Member of the Medical Advisory Board at NetScientific plc since January 6, 2016. He serves as a Member of the Scientific Advisory Board at Jecure Therapeutics, Inc. and Angion Biomedica Corp. He has been Scientific Advisor of Revive Therapeutics Ltd. since March 2017. He serves as a Member of the Advisory Board at Conatus Pharmaceuticals Inc. He serves as a Member of the Scientific Advisory Board at Galmed Pharmaceuticals Ltd.